Skip to main content
. Author manuscript; available in PMC: 2016 Nov 24.
Published in final edited form as: Eur J Neurosci. 2012 Jul 2;36(4):2461–2469. doi: 10.1111/j.1460-9568.2012.08163.x

Figure 3.

Figure 3

Cilengitide does not affect LTP or LTD whereas synthetic RGD peptide affects LTP stabilization. (a, b) Cilengitide (30 μM) has no effect on the induction and maintenance of TBS-induced LTP or LFS-induced LTD in acute hippocampal slices [LTP: cilengitide (n = 6, 11) vs. control (n = 6, 11); LTD: cilengitide (n = 5, 14) vs. control (n = 5, 12)]. (c) Disrupting RGD-sensitive integrin-ECM interactions in acute hippocampal slices by 500 μM GRGDSP slowly reverses potentiation to baseline [control (n = 7, 10), GRADSP (n = 4, 12), GRGDSP (n = 7, 8), two-way repeated-measures ANOVA; (control vs GRGDSP): t25-29.5: F1,16 = 4.87; P = 0.0423; t30-34.5: F1,16 = 7.73; P = 0.0134; t35-39.5: F1,16 = 9.95; P = 0.0061]. (d) GRGDSP (500 μM) has no effect on LTD in acute hippocampal slices [GRADSP (n = 8, 12), GRGDSP (n = 8, 12)]. Representative traces are from time points “a” (solid) and “b” (dashed). Scale bars: (a-d) = 5 ms, 0.5 mV. Error bars are ±s.e.m.